# OnCo record vimseltinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/vimseltinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "vimseltinib" ;
  schema:name "Vimseltinib"@en ;
  schema:description "Vimseltinib is a pill approved in February 2025 for tenosynovial giant cell tumour, a benign but destructive joint tumour, offering an alternative to repeated surgery."@en ;
  schema:url <https://onco.cc/drugs/vimseltinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vimseltinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (CSF1R)" ;
  schema:alternateName "Romvimza" ;
  onco:approval "US 2025: Symptomatic tenosynovial giant cell tumour where surgery would worsen function or cause severe morbidity", "EU 2025: Symptomatic TGCT where surgery has been exhausted or would cause unacceptable morbidity; 17 Sep 2025" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/tenosynovial-giant-cell-tumour/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:companies <https://onco.cc/companies/deciphera/> ;
  onco:trials <https://onco.cc/trials/motion/>, <https://onco.cc/trials/nct03069469/> .